NYMOX PHARMACEUTICAL CORPORATION

NYMOX PHARMACEUTICAL CORPORATION

March 23, 2005 13:30 ET

Nymox Makes Major Progress in Global Marketing of Company's Proprietary Alzheimer Test


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX PHARMACEUTICAL CORPORATION

NASDAQ SYMBOL: NYMX

MARCH 23, 2005 - 13:30 ET

Nymox Makes Major Progress in Global Marketing of
Company's Proprietary Alzheimer Test

MAYWOOD, N.J.--(CCNMatthews - Mar 23, 2005) -

Nymox (NASDAQ:NYMX) AlzheimAlert™ Test Now Available With CLIA
Certification in U.S. and With CE Mark in All European Countries

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) continues to make major
progress in the global marketing strategy for the Company's unique urine
testing technology for Alzheimer's disease (AD). The Company now has
attained U.S. federal and state CLIA approval in the U.S., and the CE
Mark in Europe. The Company recently announced a distribution and
marketing agreement for Italy with Alifax S.p.A.

"Further marketing and distribution agreements are being finalized in
Europe," said Paul Averback, CEO of Nymox. "There is an enormous unmet
global market for this one-of-a-kind patented technology".

Dr. Averback added, "It is estimated that in Europe, Japan, and the U.S.
there are over 100 million persons age 65 and over".

According to a recent study (Arch Neurol 2003; 60: 1119-1122), there are
an estimated 4.5 million people with Alzheimer's disease in the United
States alone; by 2050 this number is projected to increase almost three
times to 13.2 million. Worldwide estimates of the current number of
people with Alzheimer's disease range from 15 to 20 million. The annual
national direct and indirect costs of caring for Alzheimer patients in
the U.S. alone are estimated at $100 billion. The human toll on
patients, families and caregivers is incalculable.

There is an extensive scientific and medical literature on the brain
protein (neural thread protein or NTP) detected by the Company's
Alzheimer test and on its usefulness as an aid to the diagnosis of
Alzheimer's disease. Publications include, for example, Journal of
Alzheimer's Disease (2004; 6(3): 231-42) and (2001; 3: 345-353);
Cellular and Molecular Life Sciences (2003; 60: 2679-91) and (2001; 58:
844-849); Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical
Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002;
7:d989-96); Journal of Neuropathology and Experimental Neurology (2001;
60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and
(2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3:
177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis
(1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary
Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997;
100: 3093-3104).

Nymox Pharmaceutical Corporation is a biopharmaceutical company with
three unique proprietary products on the market, and a significant R&D
pipeline of drug products in development. In addition to the Company's
AlzheimAlert™ test, Nymox also developed and markets NicAlert™ and
TobacAlert™ tests that use urine or saliva to detect use of and
exposure to tobacco products. NicAlert™ has received clearance from
the U.S. Food and Drug Administration (FDA). TobacAlert™ is the first
test of its kind to accurately measure second hand smoke exposure in
individuals. The Company's TobacAlert™ product is presently available
in CVS / pharmacy® stores across the U.S.

Nymox is developing NX-1207, a novel treatment for benign prostatic
hyperplasia. NX-1207 has shown statistically significant positive
results in Phase 1 and 2 clinical trials in the U.S. NX-1207 is
currently in Phase 2 human testing in the US. Nymox also has several
other drug candidates and diagnostic technologies in development. Nymox
has U.S. and global patent rights for the use of statin drugs for the
treatment and prevention of Alzheimer's disease. The Company is
developing new antibacterial agents for the treatment of urinary tract
and other bacterial infections in humans and for the treatment of E.
coli O157:H7 contamination in meat and other food and drink products.
Nymox also is developing drug treatments aimed at the causes of
Alzheimer's disease.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. The conduct of clinical trials and the development
of drug products involve substantial risks and uncertainties and actual
results may differ materially from expectations. Promising early results
do not ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com